JARID1A (D28B10) Rabbit mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 200	Source/Isotype: Rabbit IgG	UniProt ID: #P29375	Entrez-Gene Id: 5927	
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:100		
Storage		Supplied in 10 mM sodi 0.02% sodium azide. Sto			ml BSA, 50% glycer	ol and less than	
Specificity/Sensitivity		JARID1A (D28B10) Rabbit mAb detects endogenous levels of total JARID1A protein (both isoforms). The antibody does not cross-react with other JARID proteins, including JARID1B, JARID1C and JARID1D.					
Species predicted based on 100% so homology		Rat, Bovine					
Source / Purificat	tion	Monoclonal antibody is residues surrounding G			synthetic peptide co	prresponding to	
Background		The methylation state o active and inactive regic development (1,2). Jumo histone demethylase pr tri-methyl lysine residue homology, both human separate families (3). Th four members: JARID1A JARID1D (also SMCY) (4) zinc-finger, and PHD doi JARID proteins demethy methyl histone H3 Lys4 Repressive Complex 2 (f JARID1A-NUP98 gene fu many proteins including differentiation (10-12). J multiple tumor suppress complex with HDAC1, H neuronal cells (7). JARID (15,16). JARID1D is unique repressing genes associ prostate tumors, and lo (17).	bins of the genome onji C (JmjC) doma roteins (3). The Jmj es via an oxidative s and mice contain the JARID (Jumonji// . (also RBP2 and RI . In addition to the mains, the latter of late di- and tri-me (5-7). JARID1A is a PRC2)-mediated tri sion is associated g c-Myc and HDAC ARID1B is overexp isor genes, includi DAC2, G9a, and RI 1C mutations are uely localized to the iated with cell inva-	and is crucial for prope in-containing proteins r C domain can catalyze t reaction that requires in at least 30 such protei AT-rich interactive doma BP2), JARID1B (also PLI amJC domain, these pro- f which binds to methyl thyl histone H3 Lys4; JA critical RB-interacting p anscriptional repression with myeloid leukemia 4, may play a role in cell pressed in many breast ong <i>BRCA1</i> and <i>HOXA5</i> (1 EST, which binds to and associated with X-linkec ne Y chromosome, and f asiveness (17). JARID1D i	er programming of f epresent the larges he demethylation o ron and α-ketogluta ns, which can be div in-containing prote J-1), JARID1C (also S oteins contain JmJN ated histone H3 (Ly RID1B also demeth rotein and is requir o during ES cell diffe (9). JARID1B, which fate decisions by b ancers and may act 3,14). JARID1C has represses REST targ I mental retardation unctions as a tumo s frequently mutate	the genome during it class of potential f mono-, di-, and irate (3). Based on vided into 7 in) family contains SMCX), and , BRIGHT, C5HC2 s9) (4). All four ylates mono- red for Polycomb- erentiation (8). A interacts with locking terminal t by repressing been found in a get genes in non- n and epilepsy r suppressor by ed in metastatic	
Background Refe	erences	 Kubicek, S. et al. (2000) Lin, W. and Dent, S.Y. Klose, R.J. et al. (2006) Benevolenskaya, E.V. Christensen, J. et al. (2007) Tahiliani, M. et al. (2008) van Zutven, L.J. et al. (2008) van Zutven, L.J. et al. (2001) Barrett, A. et al. (2002) Barrett, A. et al. (2002) Luc, P.J. et al. (2002) 	(2006) <i>Curr Opin</i> () <i>Nat Rev Genet</i> 7, (2007) <i>Biochem Co</i> 2007) <i>Cell</i> 128, 106 (7) <i>Mol Cell</i> 25, 801 (7) <i>Nature</i> 447, 60 (7) <i>Nature</i> 447, 60 (7) <i>Senes Dev</i> 22, 13 (2006) <i>Genes Chrc</i> (2007) <i>Genes Dev</i> 21 (7) <i>Int J Cancer</i> 12 (8) <i>Mol Cell Biol</i> 28, (9) <i>Int J Cancer</i> 10	Genet Dev 16, 137-42. 715-27. ell Biol 85, 435-43. 53-76. -12. 1-5. 45-55. <i>pmosomes Cancer</i> 45, 43 , 537-51. I, 265-75. 5312-27. I, 581-8.			

Tzschach, A. et al. (2006) *Hum Mutat* 27, 389.
 Jensen, L.R. et al. (2005) *Am J Hum Genet* 76, 227-36.
 Li, N. et al. (2016) *Cancer Res* 76, 831-43.

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key	W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key	H: Human M: Mouse
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.